BioMarin Pharmaceuticals BMRN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's operating income?
- BioMarin Pharmaceuticals (BMRN) reported operating income of $129.64M in Q1 2026.
- How has BioMarin Pharmaceuticals's operating income changed year-over-year?
- BioMarin Pharmaceuticals's operating income decreased by 42.1% year-over-year, from $223.89M to $129.64M.
- What is the long-term trend for BioMarin Pharmaceuticals's operating income?
- Over 3 years (2021 to 2024), BioMarin Pharmaceuticals's operating income has grown at a 80.5% compound annual growth rate (CAGR), from -$82.34M to $484.21M.
- What does operating income mean?
- Profit earned from core business activities before interest and taxes.
- How do you interpret operating income?
- Higher operating income indicates strong operational efficiency and successful commercial execution.
- How does operating income compare across companies?
- A primary metric for comparing the core profitability of pharmaceutical companies regardless of capital structure.